Previous Article | Next Article ![]()
Journal of Virology, November 2000, p. 10811-10815, Vol. 74, No. 22
Department of Biology, Georgia State
University, Atlanta, Georgia 30303
Received 15 May 2000/Accepted 22 August 2000
Rubella virus (RUB) is a small plus-strand RNA virus
classified in the Rubivirus genus of the family
Togaviridae. Live, attenuated RUB vaccines have been
successfully used in vaccination programs for over 25 years, making RUB
an attractive vaccine vector. In this study, such a vector was
constructed using a recently developed RUB infectious cDNA clone
(Robo). Using a standard strategy employed to produce expression
and vaccine vectors with other togaviruses, the subgenomic
promoter was duplicated to produce a recombinant construct (termed
dsRobo) that expressed reporter genes such as chloramphenicol
acetyltransferase and green fluorescent protein (GFP) under control of
the second subgenomic promoter. However, expression of the reporter
genes, as exemplified by GFP expression by dsRobo/GFP virus,
was unstable during passaging, apparently due to homologous
recombination between the subgenomic promoters leading to deletion of
the GFP gene. To improve the stability of the vector, the internal
ribosome entry site (IRES) of a picornavirus, encephalomyocarditis virus, was used instead of the second
subgenomic promoter to eliminate homology. Construction was initiated
by first replacing the subgenomic promoter in the parent Robo
infectious clone with the IRES. Surprisingly, viable virus resulted;
this virus did not synthesize a subgenomic RNA. The subgenomic promoter was then reintroduced in an orientation such that a single subgenomic RNA was produced, GFP was the initial gene on this RNA, while the RUB
structural protein open reading frame was downstream and under control
of the IRES element. GFP expression by this vector was significantly
improved in comparison to dsRobo/GFP. This strategy should be
applicable to increase the stability of other togavirus vectors.
Rubella virus (RUB) is an important
pathogen of humans. RUB is a small, quasi-spherical, enveloped,
nonsegmented, plus-strand RNA virus that is the sole member of the
Rubivirus genus in the Togaviridae family
(5). The RUB genome is roughly 10,000 nucleotides (nt)
long and is capped and polyadenylated. In infected cells, three viral
RNA species are synthesized: the genomic RNA, which also is the
mRNA for translation of the nonstructural proteins (whose
function is in viral RNA synthesis) from a long open reading frame
(ORF) at the 5' end of the genome; a complementary genome-length RNA of
minus polarity which is the template for synthesis of plus-strand RNA
species; and a subgenomic (SG) RNA which is initiated internally and
contains the sequences of the 3'-terminal one-third of the genome and
serves as the mRNA for the translation of the structural proteins
(C [capsid protein] and two envelope glycoproteins, E1 and E2) from a
second, 3'-proximal ORF. In the other togavirus genus, the
alphaviruses, synthesis of the SG RNA is directed by a short (~25-nt)
sequence located immediately upstream from the SG start site known as
the SG promoter (20).
Because RUB causes serious birth defects when infection occurs during
the first trimester of pregnancy, live, attenuated vaccines were
developed and have been used in vaccination programs in developed countries since 1970 (8). The standard vaccination strategy is universal vaccination of children at 15 to 18 months of age. The
vaccine induces an immune response in over 95% of recipients and has
been among the most successful live, attenuated vaccines developed.
Because of their effectiveness and universal acceptance, a vaccine
vector based on live, attenuated RUB vaccines would be highly desirable
for use in a pediatric setting. Immunization with a RUB vector would
result in induction of immunity against both RUB and the heterologous
virus whose genes were expressed.
Infectious cDNA clones have been developed for a number of togaviruses
including RUB (11). An infectious cDNA clone is a plasmid
containing a cDNA copy of a viral genome positioned adjacent to an RNA
polymerase promoter such that infectious in vitro transcripts can be
synthesized. The infectious cDNA clones of several alphaviruses have
been modified to produce vaccine/expression vectors, most notably
Sindbis virus (SIN) (1, 9), Semliki Forest virus (6,
19), and Venezuelan equine encephalitis virus (15). The initial alphavirus vectors were engineered by duplicating the SG
promoter, resulting in a virus that synthesized two SG RNAs, one from
which the native structural protein ORF (SP-ORF) is translated and one
from which the foreign gene is translated (alphavirus expression
vectors were most recently reviewed in reference
17). Thus, our initial RUB vector was constructed by
this strategy using the wild-type Therien strain RUB infectious clone
Robo302 (which is based on the low-copy-number plasmid pCL1921 [11]). In the alphavirus vectors, the second SG
promoter has been placed both between the ORFs and downstream of the
SP-ORF within the 3' untranslated region, which is 400 to 500 nt long in these viruses. However, since the RUB 3' untranslated region is
relatively short (60 nt) and the 3' 300 nt (including the 3' end of the
SP-ORF) appear to be necessary for efficient virus replication (2,
3), we placed the additional SG promoter between the ORFs (Fig. 1
and Table 1). Since the RUB SG promoter has not been mapped, we duplicated a region consisting of the 3'-terminal 126 nt of the nonstructural protein ORF (NSP-ORF) and the
entire 120-nt noncoding region between the NSP-ORF and the
SP-ORF. A multiple cloning site (MCS) containing convenient restriction sites (including unique XbaI, BstBI,
HpaI, and NsiI sites) was placed between the SG
promoters for insertion of foreign genes. Thus, in this construct the
SG RNA transcribed from the upstream SG promoter is translated to
produce the foreign gene, while the SG RNA transcribed from the
downstream SG promoter is equivalent to the standard SG RNA and is
translated to produce the virus structural proteins. The plasmid was
termed dsRobo302.
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Development of a Rubella Virus Vaccine Expression
Vector: Use of a Picornavirus Internal Ribosome Entry Site
Increases Stability of Expression

![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References

View larger version (23K):
[in a new window]
FIG. 1.
Genomic arrangements of the RUB constructs developed and
used in this study. Robo302 (pCL1921 plasmid backbone
[11]) and Robo402 (pBR322) contain the standard
virus genome with its modular NSP- and SP-ORFs. Robo402 was
additionally modified by the addition of an NsiI site
immediately following the NSP-ORF to produce Robo402/NsiI. The region
of the genome containing the putative SG promoter, nt 6260 to 6506, was
duplicated by PCR; two amplicons were produced, the first using primers
106 and K1 (Table 1) and the second using primers K3 and 1. Following
digestion of amplicon 1 with BglII and XbaI and
amplicon 2 with XbaI and AscI, a three-fragment
ligation was performed with Robo302 digested with BglII and
AscI. GFP was PCR amplified from SINrep/GFP plasmid
(obtained from I. Frolov) with primers that retained the initiation and
termination codons of the GFP gene but added flanking XbaI
and NsiI sites and cloned into the MCS of the dsRobo302
plasmid using these two enzymes. To make Robo402/IRES, a ~600-nt
amplicon containing the complete encephalomyocarditis virus
internal ribosome entry site (IRES) was PCR amplified from pCEN plasmid
(obtained from I. Frolov) using primers IR-5 and IR-3 (Table 1). This
amplicon was rendered blunt ended with T4 DNA polymerase and then
digested with NsiI. A second amplicon containing RUB
sequence between the second codon of the SP-ORF and AscI (nt
7313) was PCR amplified using primers IRES-R and 1 (Table 1). This
amplicon was digested with Eco47III and AscI. The
two amplicons were then combined in a three-fragment ligation with
NsiI-AscI-digested Robo402/NsiI. To produce
siRobo/GFP, the BglII-NsiI fragment of
dsRobo302/GFP was ligated into Robo402/IRES that had been
restricted with these two enzymes. An siRobo402 vector containing the
dsRobo402 MCS between the SG promoter and the IRES element was
created by similar introduction of the BglII-NsiI
fragment from dsRobo402 into Robo402/IRES. Production of in vitro
transcripts from these plasmids and subsequent transfection of Vero
cells were done as described previously (11).
TABLE 1.
PCR primer pairs used in
vector constructiona
To test expression, the reporter genes chloramphenicol
acetyltransferase (CAT) and green fluorescent protein (GFP)
were introduced into dsRobo302. When in vitro transcripts from
dsRobo302, dsRobo302/CAT, and dsRobo302/GFP were used
to transfect Vero cells, virus was recovered. CAT expression was
detected by both immunoprecipitation followed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Fig.
2) and CAT enzyme assay using lysates
from infected cells (18). In the experiment shown in Fig. 2,
CAT expression during a similar radiolabeling window from a
corresponding SIN vector, pTE5'2J/CAT, was also assayed. Due to the
growth differences and degree of cytopathic effect induced in infected
cells, radiolabeling was done at 25 h posttransfection for the SIN
vector and 41 h with the dsRobo vector. Predictably,
expression was greater with the SIN vector, but expression with the
dsRobo vector was readily detectable. When an enzyme assay
(18) was used to quantitate the difference in expression
using lysates prepared at the same times posttransfection, CAT
expression by the SIN vector was approximately 7.5 times greater than
CAT expression by the dsRobo vector (data not shown). When lysates
were prepared 4 and 6 days after transfection with dsRobo302/CAT,
CAT expression increased 1.4- and 1.8-fold in comparison with the 2-day
lysate.
|
GFP expression by the dsRobo vector was detected by examining
living Vero cell cultures infected with dsRobo/GFP virus under a microscope with epifluorescence capability (data not shown) and by
immunoprecipitation (Fig. 3), and the
percentage of cells in an infected culture expressing GFP was
determined by flow cytometry (Fig. 4).
Properties of the dsRobo and dsRobo/GFP viruses were analyzed in greater detail. The majority of plaques formed by P0
(passage 0) dsRobo and dsRobo/GFP virus (virus produced by transfected cultures) were smaller than Robo302 virus plaques; however,
~1% were similar in size to Robo302 virus plaques. P0 dsRobo and dsRobo/GFP virus titers were roughly
5 × 105 PFU/ml, in comparison to average P0 Robo302
virus titers of 5 × 106 PFU/ml. When intracellular
RNA from infected cells was analyzed, as expected, the genomic
RNAs of both dsRobo and dsRobo/GFP virus were larger than
Robo302 virus genomic RNA, and both produced an additional,
longer SG RNA not found in cells infected with Robo302 virus (Fig.
5A). The intensities of the two SG RNA
bands relative to the genomic RNA were similar to each other
and to the SG/genomic RNA ratio in Robo302 virus-infected
cells, indicating that both SG promoters retained the functional
efficiency found in standard virus.
|
|
|
When P0 dsRobo/GFP virus was passaged (multiplicity of infection [MOI] of 0.1 PFU/cell, with harvest at 5 to 6 days postinfection), the level of GFP expression diminished and was undetectable by radioimmunoprecipitation by P3 (Fig. 3A). The percentage of cells in infected cultures expressing GFP declined precipitously through P3, and GFP-positive cells were not detectable in the fourth and subsequent passages (Fig. 4). Thus, GFP expression was unstable, as has been encountered with double-subgenomic alphavirus vectors (13, 14). Analysis of intracellular viral RNA revealed that by P3, the dsRobo/GFP and similarly passaged dsRobo viruses synthesized no detectable second SG RNA, and the genomic RNA of these viruses was the same size as that of Robo302 virus (Fig. 5A). This suggests that GFP expression had been lost due to homologous recombination between the two SG promoters, which would restore the genomic RNA to the size of standard virus. Concomitant with loss of GFP expression, P2 and later-passage dsRobo and dsRobo/GFP virus produced plaques similar in size to Robo302 virus plaques.
To eliminate the possibility of homologous recombination in the RUB vector, we next investigated whether an IRES element could be incorporated into our RUB expression vector in place of the second SG promoter. Construction of this vector, described in the legend to Fig. 1, was initiated by replacing the SG promoter with the IRES in Robo402 (a pBR322 derivative of Robo302). Surprisingly, transcripts from this construct, Robo402/IRES, gave rise to viable virus which formed plaques on Vero cells. The average P0 titer of Robo402/IRES virus was 8.5 × 105 PFU/ml; the titer rose to 2.4 × 106 PFU/ml at P3 and 6.0 × 107 PFU/ml at P5. As shown in Fig. 5B, the predominant virus-specific RNA species in Robo402/IRES virus-infected cells was the genomic RNA. A faint band of with a size slightly larger than that of the standard SG RNA was present. The ratio of the intensity of this band relative to the genomic RNA was 0.08 in P1 and declined to 0.006 and 0.003 in P3 and P5, respectively (in comparison, the SG/genomic intensity ratio was 1.2 in Robo402-infected cells). Therefore, although the identity of this band was not determined (for example, it could have been due to adventitious use of the IRES as an SG promoter), it is doubtful that it plays a significant role in Robo402/IRES virus replication.
To complete construction of the vector, the SG promoter followed by the GFP gene was introduced into Robo402/IRES to produce siRobo402/GFP. Virus produced from this construct should synthesize a single SG RNA; in this SG RNA, the GFP gene is 5' proximal and is followed by the IRES and the SP-ORF (Fig. 1). Transcripts from siRobo402/GFP gave rise to virus following transfection of Vero cells. P0 titers of siRobo/GFP virus were 3 × 104 PFU/ml but rose to 4 × 106 PFU/ml at P3 and 1.2 × 107 PFU/ml at P5. GFP expression by siRobo/GFP virus was relatively stable through P5 as assayed by both immunoprecipitation (Fig. 3B) and flow cytometry of infected cultures (Fig. 4). P0 siRobo/GFP virus formed small opaque plaques, and this was the majority plaque morphology through P5, when ~10% of the plaques had Robo402 virus morphology. Analysis of intracellular virus-specific RNA revealed that the presence of the genomic RNA and an SG RNA larger than the standard SG RNA in P1 siRobo/GFP-infected cells, as expected. However, by P3, a band of intermediate size between the siRobo/GFP SG RNA and the standard SG RNA was present, and by P5 a band of similar in size to the standard SG RNA appeared. Concomitantly, a shorter genomic RNA band appeared with a size similar to the size of the standard genomic RNA. Thus, deletion events occurred during passage of siRobo/GFP virus, but at a much lower rate compared to dsRobo viruses (particularly in Fig. 4, it can be seen that GFP expression by siRobo/GFP virus declined to some extent in the passages during which these deletion events occurred).
Thus, we have successfully constructed RUB vectors which could be useful as both vaccine and expression vectors, and this is the first report of the use of RUB as a recombinant vector. The siRobo vector exhibited greater stability of foreign expression and the strategy of using an IRES to increase stability is also applicable to alphavirus vectors. Both dsRobo and siRobo vectors with MCSs have been developed. Since RUB replicates in a variety of vertebrate cell types and in most of these replication is to low titers and without accompanying cytopathogenicity (unlike the Vero cells used in this study), the niche for a RUB expression vector would be for low-level expression without a drastic effect on the cell, which has been a problem with some of the highly cytopathic alphavirus vectors (17). While the expression experiments in this study used reporter genes, we have successfully expressed a truncated form of the immunogenic E proteins of Japanese encephalitis virus in both dsRobo and siRobo as prototype vaccine candidates (data not shown). Live, attenuated RUB vaccines have been universally accepted as effective and safe in childhood immunization programs. Thus, a RUB-based vaccine would be best used in a pediatric setting to target systemic pathogens against which universal immunization was desired, such as human immunodeficiency virus, respiratory syncytial virus, or one of the hepatitis agents; a cocktail of RUB-based vaccines targeting different pathogens could be used to induce immunity simultaneously against each pathogen targeted in the cocktail. To the end of developing a RUB vector acceptable as a vaccine vector, we recently constructed an infectious cDNA clone based on the RA27/3 vaccine strain (12), the vaccine used in the United States and Europe.
While the focus of this study was vector development, the results did add to our understanding of RUB replication strategy. First, the ability of dsRobo virus to synthesize two SG RNAs with equal efficiency demonstrates that the RUB SG promoter is somewhere within the duplicated region, i.e., 170 nt upstream from the SG RNA start site. The dsRobo302/GFP construct will be of use in mapping the precise boundaries of the SG promoter. Second, we unexpectedly discovered that RUB was viable with an IRES element in place of its SG promoter. A number of other virus families of vertebrates (the caliciviruses, astroviruses, and hepatitis E virus) and plants have evolved a modular expression strategy similar to that used by togaviruses in which the nonstructural and structural proteins are translated from two different ORFs. In all of these viruses, expression of the 3'-proximal structural protein ORF is driven by an SG promoter. Our results show that an IRES can function in this capacity as well in the absence of an SG RNA. Interestingly, it was recently shown that in the insect picorna-like virus family, which have a 3'-proximal structural protein ORF and synthesize no SG RNA, expression of this ORF is driven by an IRES element (16). However, while the IRES element was retained during multiple passaging of Robo402/IRES virus, passaging of the siRoboRUB/GFP virus which contained both the SG promoter and IRES resulted in deletions within the genome and reappearance of an SG RNA similar in size to the standard SG RNA, indicating that SG RNA synthesis was preferred.
| |
ACKNOWLEDGMENTS |
|---|
Support for this study was provided by a grant from the World Health Organization and from PHS grant AI-21389 from NIAID.
We thank Birgit Neuhaus for help with image reproduction.
| |
FOOTNOTES |
|---|
* Corresponding author. Department of Biology, Georgia State University, 24 Peachtree Center Ave., Atlanta, GA 30303. Phone and fax: (404) 651-3105. E-mail: tfrey{at}gsu.edu.
Present address: Oravax, Inc., Cambridge, MA 02139.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bredenbeek, P. K.,
I. Frolov,
C. M. Rice, and S. Schlesinger.
1993.
Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs.
J. Virol.
67:6439-6446 |
| 2. |
Chen, M.-H., and T. K. Frey.
1999.
Mutagenic analysis of the 3' cis-acting elements of the rubella virus genome.
J. Virol.
73:3386-3403 |
| 3. | Derdeyn, C. A., and T. K. Frey. 1995. Characterization of defective-interfering RNAs of rubella virus generated during serial undiluted passage. Virology 206:216-226[CrossRef][Medline]. |
| 4. | Forng, R.-Y., and T. K. Frey. 1995. Identification of the rubella virus nonstructural proteins. Virology 206:843-854[CrossRef][Medline]. |
| 5. | Frey, T. K. 1994. Molecular biology of rubella virus. Adv. Virus Res. 44:69-160[Medline]. |
| 6. | Liljestrom, P., and H. Garoff. 1991. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Bio/Technology 9:1356-1361[CrossRef][Medline]. |
| 7. | Marr, L. D., A. Sanchez, and T. K. Frey. 1991. Efficient in vitro translation and processing of the rubella virus structural proteins in the presence of microsomes. Virology 180:400-405[CrossRef][Medline]. |
| 8. | Plotkin, S. A. 1999. Rubella vaccines, p. 409-439. In S. A. Plotkin, and E. A. Mortimer (ed.), Vaccines, 3rd ed. W. B. Saunders, Philadelphia, Pa. |
| 9. |
Polo, J. M.,
B. A. Belli,
D. A. Driver,
I. Frolov,
S. Sherrill,
M. J. Hariharan,
K. Townsend,
S. Perri,
S. J. Mento,
D. J. Jolly,
S. M. Chang,
S. Schlesinger, and T. W. Dubensky.
1999.
Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors.
Proc. Natl. Acad. Sci. USA
96:4598-4603 |
| 10. | Pugachev, K. V., and T. K. Frey. 1998. Rubella virus induces apoptosis in culture cells. Virology 250:359-370[CrossRef][Medline]. |
| 11. | Pugachev, K. V., E. S. Abernathy, and T. K. Frey. 1997. Improvement of the specific infectivity of the rubella virus (RUB) infectious clone: determinants of cytopathogenicity induced by RUB map to the nonstructural proteins. J. Virol. 71:562-568[Abstract]. |
| 12. | Pugachev, K. V., M. S. Galinski, and T. K. Frey. 2000. Infectious cDNA clone of the RA27/3 vaccine strain of rubella virus. Virology 273:189-197[CrossRef][Medline]. |
| 13. | Pugachev, K. V., P. W. Mason, and T. K. Frey. 1995. Sindbis vectors suppress secretion of subviral particles of Japanese encephalitis virus from mammalian cells infected with SIN-JEV recombinants. Virology 209:155-166[CrossRef][Medline]. |
| 14. | Pugachev, K. V., P. W. Mason, R. E. Shope, and T. K. Frey. 1995. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology 212:587-594[CrossRef][Medline]. |
| 15. | Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston, and J. F. Smith. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401[CrossRef][Medline]. |
| 16. |
Sasaki, J., and N. Nakashima.
1999.
Translation initiation at the CUU codon is mediated by the internal ribosome entry site of an insect picorna-like virus in vitro.
J. Virol.
73:1219-1226 |
| 17. | Schlesinger, S., and T. W. Dubensky. 1999. Alphavirus vectors for gene expression and vaccines. Curr. Opin. Biotechnol. 10:434-439[CrossRef][Medline]. |
| 18. | Seed, B., and J. Y. Sheen. 1988. A simple phase-extraction assay for chloramphenicol acyltransferase activity. Gene 67:271-277[CrossRef][Medline]. |
| 19. |
Smerdou, C., and P. Liljestrom.
1999.
Two-helper RNA system for production of recombinant Semliki Forest virus particles.
J. Virol.
73:1092-1098 |
| 20. |
Strauss, J. H., and E. G. Strauss.
1994.
The alphaviruses: gene expression, replication, and evolution.
Microbiol. Rev.
58:491-562 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»